Tenax Therapeutics (TENX) Financials

Tenax Therapeutics logo
$1.42 -0.06 (-4.05%)
Closing price 04:00 PM Eastern
Extended Trading
$1.46 +0.04 (+2.46%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Annual Income Statements for Tenax Therapeutics

Annual Income Statements for Tenax Therapeutics

This table shows Tenax Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders
-14 -44 -8.84 -14 -8.39 -9.85 -32 11 -7.71 -18 -53
Consolidated Net Income / (Loss)
-14 -44 -8.84 -14 -8.39 -9.85 -32 11 -7.71 -18 -53
Net Income / (Loss) Continuing Operations
-14 -44 -8.84 -6.81 -8.39 -9.88 -33 -11 -7.71 -18 -53
Total Pre-Tax Income
-14 -52 -8.84 -6.89 -8.56 -9.88 -33 -11 -7.71 -18 -53
Total Operating Income
-15 -53 -9.21 -6.89 -8.56 9.87 -33 11 -8.23 -19 -56
Total Gross Profit
0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue
0.05 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses
15 53 9.21 6.89 8.56 9.89 33 11 8.23 19 56
Selling, General & Admin Expense
7.17 6.25 5.68 5.65 5.08 5.31 7.58 5.68 5.01 6.79 24
Research & Development Expense
6.66 13 3.53 1.24 3.47 4.56 25 5.38 3.23 13 33
Total Other Income / (Expense), net
0.71 0.65 0.36 0.00 0.00 0.00 0.25 -0.01 0.52 1.89 3.79
Interest Expense
0.05 - - - 0.00 -0.00 0.00 0.00 0.02 0.02 0.00
Interest & Investment Income
- - - - - - - - 0.48 1.91 3.82
Other Income / (Expense), net
0.76 0.65 0.36 - 0.00 - 0.25 -0.01 0.06 0.00 -0.03
Basic Earnings per Share
($0.50) ($31.24) ($6.27) ($9.04) ($1.35) ($0.95) ($31.56) ($600.71) ($31.04) ($1.15) ($1.34)
Weighted Average Basic Shares Outstanding
28.08M 1.41M 1.41M 1.56M 6.20M 10.37M 1.03M 18.39K 248.45K 15.27M 39.22M
Diluted Earnings per Share
($0.50) ($31.24) ($6.27) ($9.04) ($1.35) ($0.95) ($31.56) ($600.71) ($31.04) ($1.15) ($1.34)
Weighted Average Diluted Shares Outstanding
28.08M 1.41M 1.41M 1.56M 6.20M 10.37M 1.03M 18.39K 248.45K 15.27M 39.22M
Weighted Average Basic & Diluted Shares Outstanding
28.08M 1.41M 1.41M 1.56M 6.20M 10.37M 1.03M 18.39K 248.45K 3.97M 17.20M

Quarterly Income Statements for Tenax Therapeutics

This table shows Tenax Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Income / (Loss) Attributable to Common Shareholders
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Consolidated Net Income / (Loss)
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Net Income / (Loss) Continuing Operations
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Total Pre-Tax Income
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Total Operating Income
-3.91 -3.67 -4.62 -7.30 -11 -12 -17 -16 -17 -19 -18
Total Gross Profit
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Cost of Revenue
0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00
Total Operating Expenses
3.91 3.67 4.62 7.30 11 12 17 16 17 19 18
Selling, General & Admin Expense
1.23 1.34 1.51 2.70 5.66 5.67 6.48 5.91 5.03 5.93 5.66
Research & Development Expense
2.68 2.33 3.11 4.59 5.68 6.12 10 11 12 13 12
Total Other Income / (Expense), net
0.11 0.10 0.66 1.03 0.93 0.95 1.00 0.91 0.86 0.98 1.02
Interest & Investment Income
0.12 0.10 0.67 1.03 0.93 0.95 1.02 0.92 0.86 0.98 1.04
Other Income / (Expense), net
- 0.00 0.00 - 0.00 -0.01 -0.02 - -0.00 0.00 -0.01
Basic Earnings per Share
($3.12) ($1.83) ($0.19) ($0.41) ($0.28) ($0.27) ($0.40) ($0.40) ($0.35) ($0.35) ($0.31)
Weighted Average Basic Shares Outstanding
1.22M 1.96M 21.16M 15.27M 36.58M 39.57M 39.74M 39.22M 45.23M 50.87M 53.45M
Diluted Earnings per Share
($3.12) ($1.83) ($0.19) ($0.41) ($0.28) ($0.27) ($0.40) ($0.40) ($0.35) ($0.35) ($0.31)
Weighted Average Diluted Shares Outstanding
1.22M 1.96M 21.16M 15.27M 36.58M 39.57M 39.74M 39.22M 45.23M 50.87M 53.45M
Weighted Average Basic & Diluted Shares Outstanding
1.22M 1.96M 21.16M 3.97M 4.15M 4.56M 6.24M 17.20M 26.53M 37.42M 45.54M

Annual Cash Flow Statements for Tenax Therapeutics

This table details how cash moves in and out of Tenax Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents
-50 6.34 -8.39 11 -7.46 21 -0.67 -3.46 7.67 85 2.71
Net Cash From Operating Activities
-9.75 -16 -12 -5.50 -7.56 -9.27 -11 -11 -5.90 -15 -36
Net Cash From Continuing Operating Activities
-9.75 -16 -12 -5.50 -7.56 10 -53 -11 -5.90 -15 -36
Net Income / (Loss) Continuing Operations
-14 -44 -8.84 -14 -8.39 9.85 -32 -11 -7.71 -18 -53
Consolidated Net Income / (Loss)
-14 -44 -8.84 -14 -8.39 9.85 -32 -11 -7.71 -18 -53
Non-Cash Adjustments To Reconcile Net Income
1.58 33 0.39 7.94 0.27 0.35 -21 0.37 0.22 1.15 19
Changes in Operating Assets and Liabilities, net
1.93 -6.04 -3.89 0.61 0.46 0.10 -0.57 -0.82 1.58 1.64 -2.36
Net Cash From Investing Activities
-41 22 3.75 7.35 -0.00 0.02 0.45 -0.00 0.00 0.00 0.00
Net Cash From Continuing Investing Activities
-41 22 3.75 7.35 -0.00 0.02 0.45 -0.00 0.00 0.00 0.00
Sale of Property, Plant & Equipment
0.01 0.08 - - - - - - 0.00 0.00 0.00
Net Cash From Financing Activities
0.28 0.00 0.00 8.91 0.10 11 9.74 7.93 14 100 39
Net Cash From Continuing Financing Activities
0.28 0.00 0.00 8.91 0.10 11 9.74 7.93 14 100 39
Repayment of Debt
-0.44 - - - - - - 0.00 -0.62 -0.50 0.00
Issuance of Common Equity
0.54 - - - 0.00 8.66 9.19 - - 100 23
Other Financing Activities, net
- - - 0.00 0.10 1.69 0.54 0.00 0.00 0.07 15
Cash Interest Paid
0.00 - - - - - - - 0.02 0.02 0.00

Quarterly Cash Flow Statements for Tenax Therapeutics

This table details how cash moves in and out of Tenax Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
Net Change in Cash & Equivalents
2.76 -3.17 89 -3.46 17 -5.99 -6.09 -1.80 21 -0.78 -4.25
Net Cash From Operating Activities
-5.17 -3.03 -3.09 -3.53 -6.97 -6.26 -9.16 -13 -9.31 -14 -12
Net Cash From Continuing Operating Activities
-5.17 -3.03 -3.09 -3.53 -6.97 -6.26 -9.16 -13 -9.31 -14 -12
Net Income / (Loss) Continuing Operations
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Consolidated Net Income / (Loss)
-3.80 -3.58 -3.96 -6.27 -10 -11 -16 -16 -16 -18 -17
Non-Cash Adjustments To Reconcile Net Income
0.13 0.03 0.02 0.97 4.14 4.61 5.62 4.79 2.84 3.33 3.54
Changes in Operating Assets and Liabilities, net
-1.49 0.51 0.85 1.77 -0.70 -0.03 1.03 -2.67 3.57 0.32 0.69
Net Cash From Financing Activities
7.92 -0.13 92 0.07 24 0.28 3.06 12 30 13 8.23
Net Cash From Continuing Financing Activities
7.92 -0.13 92 0.07 24 0.28 3.06 12 30 13 8.23
Other Financing Activities, net
0.00 -0.00 1.83 -1.76 0.35 0.28 3.06 12 30 13 8.23

Annual Balance Sheets for Tenax Therapeutics

This table presents Tenax Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets
83 23 9.89 13 6.37 6.87 5.99 3.40 12 97 104
Total Current Assets
18 14 8.06 13 6.18 6.80 5.69 3.21 12 97 104
Cash & Equivalents
7.93 10.00 1.60 12 4.91 6.25 5.58 2.12 9.79 95 98
Prepaid Expenses
0.25 0.28 0.29 0.46 0.78 0.08 0.11 0.74 1.64 1.77 5.64
Other Current Assets
0.06 - - - - - 0.00 0.35 0.25 0.06 1.02
Plant, Property, & Equipment, net
0.05 0.02 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00
Total Noncurrent Assets
65 9.69 1.82 0.01 0.18 0.07 0.30 0.19 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
83 23 9.89 13 6.37 6.87 5.99 3.40 12 97 104
Total Liabilities
12 6.20 1.01 1.57 2.59 2.24 1.75 1.91 3.59 4.69 7.16
Total Current Liabilities
4.52 6.20 1.01 1.57 2.53 2.12 1.56 1.85 3.59 4.69 7.16
Accounts Payable
1.18 0.73 0.61 0.75 1.66 0.76 0.86 0.45 2.07 3.16 6.04
Accrued Expenses
2.66 5.25 0.36 0.82 0.87 1.24 0.70 0.78 1.01 1.54 1.12
Total Noncurrent Liabilities
7.96 0.00 0.00 0.00 0.06 0.12 0.18 0.06 0.00 0.00 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
70 17 8.88 12 3.77 4.63 4.24 1.49 8.10 92 97
Total Preferred & Common Equity
70 17 8.88 12 3.77 4.63 4.24 1.49 8.10 92 97
Preferred Stock
0.00 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
70 17 8.88 12 3.77 4.62 4.24 1.49 8.10 92 97
Common Stock
221 222 222 240 240 251 283 291 305 407 465
Retained Earnings
-151 -205 -213 -228 -236 -246 -278 -290 -297 -315 -367

Quarterly Balance Sheets for Tenax Therapeutics

This table presents Tenax Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026 9/30/2026
Total Assets
12 14 11 100 112 106 103 123 122 117
Total Current Assets
12 14 11 100 112 106 103 123 122 117
Cash & Equivalents
11 13 9.38 98 111 105 99 119 118 114
Prepaid Expenses
0.47 1.84 1.18 1.44 0.52 0.40 3.44 4.32 3.42 3.18
Other Current Assets
0.27 0.07 0.05 0.03 0.09 - - 0.11 0.27 0.11
Plant, Property, & Equipment, net
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity
12 14 11 100 112 106 103 123 122 117
Total Liabilities
0.60 2.03 1.74 2.56 2.77 2.53 6.60 8.49 8.07 8.36
Total Current Liabilities
0.60 2.03 1.74 2.56 2.77 2.53 6.60 8.49 8.07 8.36
Accounts Payable
0.13 1.08 0.87 1.58 1.84 0.56 5.61 6.35 6.80 6.57
Accrued Expenses
0.29 0.54 0.59 0.98 0.93 1.97 0.99 2.14 1.28 1.79
Total Noncurrent Liabilities
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Commitments & Contingencies
- 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
11 12 8.88 97 109 103 96 115 114 109
Total Preferred & Common Equity
11 12 8.88 97 109 103 96 115 114 109
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
11 12 8.88 97 109 103 96 115 114 109
Common Stock
305 313 314 406 435 439 448 498 515 526
Retained Earnings
-294 -301 -305 -309 -325 -336 -352 -383 -401 -418

Annual Metrics And Ratios for Tenax Therapeutics

This table displays calculated financial ratios and metrics derived from Tenax Therapeutics' official financial filings.

Metric 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding
28,119,436.00 28,119,934.00 28,236,546.00 1,465,496.00 6,741,860.00 12,619,369.00 25,206,914.00 44,696,215.00 23,862,434.00 3,408,906.00 6,243,575.00
DEI Adjusted Shares Outstanding
879.00 879.00 882.00 916.00 4,214.00 7,887.00 15,754.00 27,935.00 298,280.00 3,408,906.00 6,243,575.00
DEI Earnings Per Adjusted Shares Outstanding
-16,020.26 -49,970.31 -10,022.32 -15,441.10 -1,992.02 -1,249.00 -2,061.34 395.49 -25.85 -5.16 -8.42
Growth Metrics
- - - - - - - - - - -
Revenue Growth
-82.93% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
22.95% 0.00% 83.16% 21.39% -24.38% 218.23% -423.88% 134.48% -173.17% -138.80% -189.43%
EBIT Growth
18.87% 0.00% 82.99% 22.04% -24.11% 215.34% -429.08% 134.01% -173.99% -138.56% -189.43%
NOPAT Growth
10.80% 0.00% 82.52% 25.12% -24.11% 215.34% -431.66% 133.77% -174.50% -136.75% -189.24%
Net Income Growth
27.94% 0.00% 79.88% -60.01% 40.65% -17.36% -229.64% 134.02% -169.80% -128.27% -198.82%
EPS Growth
81.55% 0.00% 79.88% -44.18% 85.07% 29.63% -229.64% 134.02% -169.80% 96.30% -16.52%
Operating Cash Flow Growth
-5.26% 0.00% 23.51% 54.70% -37.40% -22.72% -17.08% -4.90% 48.16% -150.86% -141.71%
Free Cash Flow Firm Growth
78.12% 0.00% 0.00% 58.25% -24.20% 230.65% -428.70% 127.35% -171.48% -161.74% -249.17%
Invested Capital Growth
-9.97% 0.00% 86.14% -66.53% -49.24% -13.23% 27.32% 99.50% -17,869.57% -139.56% 82.72%
Revenue Q/Q Growth
37.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
32.46% 0.00% 82.01% 44.51% -47.47% 186.12% -187.62% 121.00% -281.08% 12.38% -19.45%
EBIT Q/Q Growth
30.30% 0.00% 81.69% 44.24% -47.06% 184.21% -188.23% 120.74% -281.43% 12.38% -19.45%
NOPAT Q/Q Growth
26.54% 0.00% 80.94% 44.24% -47.06% 184.21% -188.92% 120.56% -288.48% 12.38% -19.38%
Net Income Q/Q Growth
27.58% 0.00% 77.89% -20.49% 36.11% 13.77% -5.93% 196.36% -177.56% 15.04% -21.40%
EPS Q/Q Growth
-194.34% 0.00% 77.89% -12.58% 30.77% 24.60% -5.93% 196.36% -177.56% -69.12% -22.94%
Operating Cash Flow Q/Q Growth
12.18% 0.00% 13.06% 1.51% -7.52% -2.90% -7.75% 8.66% 8.01% -18.88% -38.16%
Free Cash Flow Firm Q/Q Growth
48.22% 0.00% 0.00% 51.94% -47.50% 192.10% -190.68% 116.47% -258.64% 15.42% -34.98%
Invested Capital Q/Q Growth
-11.86% 0.00% 5.67% -407.91% -175.36% -73.87% -20.07% -104.50% -472.78% -162.72% 84.36%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
-26,857.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
-30,062.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
-28,526.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
-28,571.63% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
99.81% 84.47% 99.97% 205.19% 98.12% 99.67% 99.22% -99.83% 100.00% 100.00% 100.00%
Interest Burden Percent
100.35% 100.00% 100.00% 100.00% 100.00% -100.17% 100.79% -100.21% 94.37% 90.30% 93.23%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
-43.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
-36.82% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
25.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-18.37% -256.25% -67.94% -136.97% -108.01% -234.61% -732.21% 385.12% -160.80% -35.17% -55.64%
Cash Return on Invested Capital (CROIC)
-33.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-15.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
-15.97% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-18.37% -256.25% -67.94% -136.96% -108.01% -234.58% -732.11% 385.12% -160.80% -35.17% -55.64%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-10 -37 -6.44 -4.83 -5.99 6.91 -23 7.74 -5.76 -14 -39
NOPAT Margin
-21,043.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-7.00% -32.32% -15.26% -83.21% -26.35% -282.42% -158.72% 93.49% -36.09% -7.60% -13.65%
Return On Investment Capital (ROIC_SIMPLE)
-14.71% -215.01% -72.55% -40.99% -158.75% 141.83% -539.73% 365.46% -67.03% -14.83% -40.66%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
14,549.32% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
13,513.75% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
30,162.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-14 -52 -8.84 -6.89 -8.56 9.87 -32 11 -8.17 -19 -56
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-13 -51 -8.64 -6.79 -8.45 9.99 -32 11 -8.16 -19 -56
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
1.37 3.20 1.56 0.15 2.52 5.08 6.18 3.34 0.81 0.23 0.78
Price to Tangible Book Value (P/TBV)
2.59 3.20 1.56 0.15 2.52 5.08 6.18 3.34 0.81 0.23 0.78
Price to Revenue (P/Rev)
1,951.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.45 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 221.88% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
2.15 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
977.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 1.70 0.00 0.31 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 1.72 0.00 0.32 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 2.46 0.00 0.45 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 2.39 0.00 0.54 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.05 0.00 0.42 0.06 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.69 -1.28 -1.21 -1.08 -1.17 -1.41 -1.36 -1.23 -1.13 -1.04 -1.02
Leverage Ratio
1.15 1.36 1.28 1.12 1.27 1.58 1.45 1.64 1.57 1.08 1.06
Compound Leverage Factor
1.15 1.36 1.28 1.12 1.27 -1.58 1.46 -1.64 1.48 0.98 0.99
Debt to Total Capital
0.14% 0.00% 0.00% 0.00% 0.00% 5.02% 0.00% 29.49% 5.83% 0.00% 0.00%
Short-Term Debt to Total Capital
0.14% 0.00% 0.00% 0.00% 0.00% 2.47% 0.00% 29.49% 5.83% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 2.55% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
99.86% 100.00% 100.00% 100.00% 100.00% 94.95% 100.00% 70.51% 94.17% 100.00% 100.00%
Debt to EBITDA
-0.01 0.00 0.00 0.00 0.00 0.02 0.00 0.06 -0.06 0.00 0.00
Net Debt to EBITDA
3.63 0.00 0.00 0.00 0.00 -0.65 0.00 -0.13 1.14 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.01 0.00 0.00 0.00 0.00 0.04 0.00 0.08 -0.09 0.00 0.00
Net Debt to NOPAT
4.63 0.00 0.00 0.00 0.00 -0.94 0.00 -0.19 1.61 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
1.71 -13.94 -24.09 -23.88 -53.49 -38.31 -73.12 -106.31 -35.99 -1.38 0.78
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.02% 0.01% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
3.88 2.20 7.99 8.51 2.44 3.21 3.64 1.74 3.26 20.60 14.57
Quick Ratio
3.81 2.15 7.71 8.22 2.13 3.17 3.57 1.15 2.73 20.21 13.63
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-7.89 0.00 -11 -4.39 -5.45 7.12 -23 6.40 -4.58 -12 -42
Operating Cash Flow to CapEx
0.00% 0.00% -267,589.09% -72,408.97% -211,420.73% -265,697.88% -206,706.07% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-160.71 0.00 0.00 0.00 0.00 0.00 -24,671.47 1,441.42 -190.73 -520.90 0.00
Operating Cash Flow to Interest Expense
-198.63 0.00 0.00 0.00 0.00 0.00 -11,439.62 -2,563.26 -246.00 -643.96 0.00
Operating Cash Flow Less CapEx to Interest Expense
-198.58 0.00 0.00 0.00 0.00 0.00 -11,445.16 -2,563.26 -245.88 -643.96 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.56 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
417.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
417.81 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
22 -4.73 -0.65 -1.09 -1.63 -1.84 -1.34 -0.01 -1.19 -2.86 -0.49
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-2.48 0.00 4.07 -0.44 -0.54 -0.22 0.50 1.33 -1.19 -1.67 2.36
Enterprise Value (EV)
48 33 4.30 -11 4.11 17 21 3.48 -2.74 -74 -21
Market Capitalization
96 55 14 1.77 9.51 23 26 4.98 6.55 21 76
Book Value per Share
$2.50 $0.61 $0.31 $8.03 $0.56 $0.37 $0.17 $0.03 $0.34 $26.99 $15.55
Tangible Book Value per Share
$1.32 $0.61 $0.31 $8.03 $0.56 $0.37 $0.17 $0.03 $0.34 $26.99 $15.55
Total Capital
71 17 8.88 12 3.77 4.87 4.24 2.12 8.60 92 97
Total Debt
0.10 0.00 0.00 0.00 0.00 0.24 0.00 0.62 0.50 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00 0.00 0.00 0.00
Net Debt
-48 -22 -9.54 -13 -5.40 -6.47 -5.58 -1.50 -9.29 -95 -98
Capital Expenditures (CapEx)
-0.00 -0.07 0.00 0.01 0.00 0.00 0.01 0.00 -0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-4.03 -5.85 -0.67 -1.11 -1.75 -1.92 -1.46 -0.14 -1.19 -2.86 -0.49
Debt-free Net Working Capital (DFNWC)
13 7.43 7.05 12 3.65 4.80 4.13 1.98 8.60 92 97
Net Working Capital (NWC)
13 7.43 7.05 12 3.65 4.68 4.13 1.36 8.10 92 97
Net Nonoperating Expense (NNE)
3.71 7.07 2.40 9.32 2.41 17 9.56 -3.31 1.95 3.96 13
Net Nonoperating Obligations (NNO)
-48 -22 -9.54 -13 -5.40 -6.47 -5.58 -1.50 -9.29 -95 -98
Total Depreciation and Amortization (D&A)
0.82 0.67 0.20 0.10 0.11 0.12 0.12 0.11 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
-8,181.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
26,567.64% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
26,364.42% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($16,000.00) ($49,920.00) ($10,032.00) ($14,464.00) ($2,160.00) $0.00 ($2,528.00) ($600.80) ($31.04) ($1.15) ($1.34)
Adjusted Weighted Average Basic Shares Outstanding
879.00 879.00 893.00 3.85K 4.76K 0.00 15.75K 279.98K 1.96M 15.27M 39.22M
Adjusted Diluted Earnings per Share
($16,000.00) ($49,920.00) ($10,032.00) ($14,464.00) ($2,160.00) $0.00 ($2,528.00) ($600.80) ($31.04) ($1.15) ($1.34)
Adjusted Weighted Average Diluted Shares Outstanding
879.00 879.00 893.00 3.85K 4.76K 0.00 15.75K 279.98K 1.96M 15.27M 39.22M
Adjusted Basic & Diluted Earnings per Share
($16,000.00) ($49,920.00) ($10,032.00) ($14,464.00) ($2,160.00) $0.00 ($2,528.00) ($600.80) ($31.04) $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
877.00 879.00 882.00 978.00 3.87K 0.00 12.86K 18.39K 248.45K 3.97M 17.20M
Normalized Net Operating Profit after Tax (NOPAT)
-9.65 -14 -6.44 -4.83 -5.99 6.91 -23 7.74 -5.76 -14 -39
Normalized NOPAT Margin
-19,574.15% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
-28,625.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-286.45 0.00 0.00 0.00 0.00 0.00 -34,218.56 2,485.58 -340.46 -847.52 0.00
NOPAT to Interest Expense
-211.32 0.00 0.00 0.00 0.00 0.00 -24,140.96 1,741.36 -240.16 -593.30 0.00
EBIT Less CapEx to Interest Expense
-286.41 0.00 0.00 0.00 0.00 0.00 -34,224.09 2,485.58 -340.33 -847.52 0.00
NOPAT Less CapEx to Interest Expense
-211.27 0.00 0.00 0.00 0.00 0.00 -24,146.49 1,741.36 -240.03 -593.30 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Tenax Therapeutics

This table displays calculated financial ratios and metrics derived from Tenax Therapeutics' official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026 9/30/2026
DEI Shares Outstanding
1,958,245.00 1,958,245.00 3,408,906.00 3,408,906.00 3,970,385.00 4,148,495.00 4,562,500.00 6,243,575.00 17,197,613.00 26,525,159.00 37,423,917.00
DEI Adjusted Shares Outstanding
1,958,245.00 1,958,245.00 3,408,906.00 3,408,906.00 3,970,385.00 4,148,495.00 4,562,500.00 6,243,575.00 17,197,613.00 26,525,159.00 37,423,917.00
DEI Earnings Per Adjusted Shares Outstanding
-1.94 -1.83 -1.16 -1.84 -2.62 -2.61 -3.46 -2.49 -0.91 -0.67 -0.45
Growth Metrics
- - - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth
-179.51% -396.43% -318.05% 27.92% -190.05% -221.55% -264.17% -125.48% -46.21% -59.17% -5.46%
EBIT Growth
-179.33% -396.67% -318.15% 27.96% -190.05% -221.55% -264.17% -125.48% -46.21% -59.17% -5.46%
NOPAT Growth
-153.92% -396.97% -318.15% 27.40% -190.05% -221.22% -263.85% -125.48% -46.17% -59.29% -5.49%
Net Income Growth
-170.05% -423.14% -300.86% 33.21% -173.97% -203.41% -298.99% -147.97% -51.00% -64.13% -5.69%
EPS Growth
74.21% 54.25% -102.87% 96.69% 91.03% 85.25% -110.53% 2.44% -25.00% -29.63% 22.50%
Operating Cash Flow Growth
-198.20% -231.10% -48.33% -200.17% -34.86% -106.63% -196.57% -280.35% -33.62% -125.93% -36.31%
Free Cash Flow Firm Growth
-6.62% -741.09% -239.39% 41.14% -106.84% -193.14% -431.06% -303.26% -76.67% -71.53% -8.29%
Invested Capital Growth
-22.13% -231.82% -439.93% -139.56% -834.87% -830.43% -190.29% 82.72% -88.45% -105.72% -60.54%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
61.38% 6.11% -25.86% -57.93% -55.42% -4.08% -42.54% 2.21% -0.78% -13.31% 5.56%
EBIT Q/Q Growth
61.40% 6.11% -25.86% -57.93% -55.42% -4.08% -42.54% 2.21% -0.78% -13.31% 5.56%
NOPAT Q/Q Growth
61.10% 6.09% -25.82% -57.93% -55.42% -4.00% -42.52% 2.12% -0.75% -13.34% 5.62%
Net Income Q/Q Growth
59.51% 5.90% -10.80% -58.22% -66.08% -4.22% -45.70% 1.67% -1.13% -13.28% 6.17%
EPS Q/Q Growth
74.80% 41.35% 89.62% -115.79% 31.71% 3.57% -48.15% 0.00% 12.50% 0.00% 11.43%
Operating Cash Flow Q/Q Growth
-339.66% 41.33% -1.85% -14.25% -97.53% 10.10% -46.18% -46.53% 30.61% -52.00% 11.81%
Free Cash Flow Firm Q/Q Growth
54.63% 18.33% 15.75% -88.53% -59.44% -15.75% -52.63% -43.16% 30.15% -12.39% 3.65%
Invested Capital Q/Q Growth
124.59% -178.10% -374.76% -162.72% 24.56% 1.11% -48.12% 84.36% -722.47% -7.95% -15.60%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent
97.19% 97.41% 85.75% 85.91% 91.80% 91.92% 93.95% 94.47% 94.81% 94.78% 94.16%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-75.66% -133.81% -38.19% -35.17% -39.78% -56.12% -44.80% -55.64% -51.71% -59.80% -64.20%
Cash Return on Invested Capital (CROIC)
-2,190.25% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)
-75.66% -133.81% -38.19% -35.17% -39.78% -56.12% -44.80% -55.64% -51.71% -59.80% -64.20%
Return on Equity Simple (ROE_SIMPLE)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)
-2.74 -2.57 -3.23 -5.11 -7.94 -8.25 -12 -12 -12 -13 -12
NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)
-8.16% -9.08% -1.33% -2.23% -4.00% -4.53% -4.09% -4.18% -3.58% -4.17% -4.03%
Return On Investment Capital (ROIC_SIMPLE)
-21.31% -28.07% -3.33% -5.55% -7.26% -7.99% -12.23% -11.86% -10.12% -11.58% -11.42%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)
-3.91 -3.67 -4.62 -7.30 -11 -12 -17 -16 -17 -19 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-3.91 -3.67 -4.62 -7.30 -11 -12 -17 -16 -17 -19 -18
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
0.67 0.67 0.12 0.23 0.24 0.23 0.36 0.78 2.40 3.40 0.65
Price to Tangible Book Value (P/TBV)
0.67 0.67 0.12 0.23 0.24 0.23 0.36 0.78 2.40 3.40 0.65
Price to Revenue (P/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.03 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.97 -1.00 -1.01 -1.04 -1.02 -1.02 -1.02 -1.02 -1.03 -1.03 -1.04
Leverage Ratio
1.11 1.12 1.03 1.08 1.04 1.04 1.05 1.06 1.05 1.05 1.07
Compound Leverage Factor
1.08 1.09 0.88 0.93 0.95 0.95 0.98 1.00 1.00 0.99 1.01
Debt to Total Capital
3.22% 3.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
3.22% 3.05% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
96.78% 96.95% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
-0.04 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
1.15 0.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
-0.06 -0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
1.64 0.84 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
-26.55 -38.27 -0.55 -0.97 2.41 2.03 -1.05 2.04 15.76 24.68 0.70
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
7.12 6.10 38.95 20.60 40.48 41.89 15.58 14.57 14.52 15.07 14.01
Quick Ratio
6.18 5.39 38.38 20.21 40.26 41.73 15.06 13.63 13.99 14.61 13.61
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.65 -2.17 -1.83 -3.44 -5.49 -6.35 -9.69 -14 -9.69 -11 -10
Operating Cash Flow to CapEx
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense
-331.61 -240.75 -260.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
-645.75 -336.78 -441.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
-645.75 -336.78 -441.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
0.29 -0.23 -1.09 -2.86 -2.16 -2.13 -3.16 -0.49 -4.06 -4.39 -5.07
Invested Capital Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital
-0.08 -0.40 -1.41 -1.67 -2.45 -1.90 -2.07 2.36 -1.91 -2.25 -1.91
Enterprise Value (EV)
-3.83 -3.20 -87 -74 -85 -82 -65 -21 156 268 -43
Market Capitalization
8.30 5.90 12 21 26 24 35 76 275 386 71
Book Value per Share
$6.35 $4.53 $28.52 $26.99 $27.53 $24.91 $21.09 $15.55 $6.67 $4.28 $2.90
Tangible Book Value per Share
$6.35 $4.53 $28.52 $26.99 $27.53 $24.91 $21.09 $15.55 $6.67 $4.28 $2.90
Total Capital
13 9.15 97 92 109 103 96 97 115 114 109
Total Debt
0.41 0.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-12 -9.11 -98 -95 -111 -105 -99 -98 -119 -118 -114
Capital Expenditures (CapEx)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.29 -0.23 -1.09 -2.86 -2.16 -2.13 -3.16 -0.49 -4.06 -4.39 -5.07
Debt-free Net Working Capital (DFNWC)
13 9.15 97 92 109 103 96 97 115 114 109
Net Working Capital (NWC)
12 8.87 97 92 109 103 96 97 115 114 109
Net Nonoperating Expense (NNE)
1.06 1.01 0.73 1.16 2.47 2.59 4.04 4.03 4.11 4.65 4.29
Net Nonoperating Obligations (NNO)
-12 -9.11 -98 -95 -111 -105 -99 -98 -119 -118 -114
Total Depreciation and Amortization (D&A)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
($3.12) ($1.83) $0.19 ($0.41) ($0.28) ($0.27) ($0.40) ($0.40) ($0.35) ($0.35) ($0.31)
Adjusted Weighted Average Basic Shares Outstanding
1.96M 3.41M 3.41M 15.27M 36.58M 39.57M 39.74M 39.22M 45.23M 50.87M 53.45M
Adjusted Diluted Earnings per Share
($3.12) ($1.83) $0.19 ($0.41) ($0.28) ($0.27) ($0.40) ($0.40) ($0.35) ($0.35) ($0.31)
Adjusted Weighted Average Diluted Shares Outstanding
1.96M 3.41M 3.41M 15.27M 36.58M 39.57M 39.74M 39.22M 45.23M 50.87M 53.45M
Adjusted Basic & Diluted Earnings per Share
($3.12) ($1.83) $0.19 ($0.41) $0.00 $0.00 $0.00 ($0.40) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
1.22M 1.96M 21.16M 3.97M 4.15M 4.56M 6.24M 17.20M 26.53M 37.42M 45.54M
Normalized Net Operating Profit after Tax (NOPAT)
-2.74 -2.57 -3.23 -5.11 -7.94 -8.25 -12 -12 -12 -13 -12
Normalized NOPAT Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
-488.63 -407.78 -659.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
-342.04 -285.52 -461.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
-488.63 -407.78 -659.86 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
-342.04 -285.52 -461.90 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Tenax Therapeutics (NASDAQ: TENX) remains a development-stage company with no reported revenue across the periods provided. The company continues to fund research and corporate operations through financing rather than operating cash flow, leaving clinical progress and future capital access as the key drivers of its financial outlook.

  • Strong cash position: Cash and equivalents totaled $118.0 million at June 30, 2026, up from $9.4 million at June 30, 2024. Current assets of $121.7 million significantly exceeded current liabilities of $8.1 million.
  • Limited debt burden: Tenax reported no noncurrent liabilities and no traditional short-term debt in the latest balance sheet. Total liabilities represented only about 6.6% of total assets, providing a relatively strong balance-sheet cushion.
  • Interest income provides a modest offset: Interest and investment income was $981,000 in Q2 2026, compared with $104,000 in Q2 2024, reflecting the benefit of holding a larger cash balance.
  • Potential operating runway: The latest cash balance equaled approximately eight quarters of Q2 2026 operating cash burn if spending remained near $14.2 million per quarter. This is only a rough estimate because research spending and financing activity have fluctuated substantially.
  • Cash levels have been supported primarily by financing: Financing provided $13.4 million in Q2 2026 and $30.5 million in Q1 2026, offsetting operating cash outflows. This has preserved liquidity but does not represent internally generated funding.
  • Prepaid expenses remain material: Prepaid expenses were $3.4 million at June 30, 2026, or roughly 3% of total assets. The balance has declined from $4.3 million in Q1 2026 but remains a notable use of working capital.
  • No revenue or gross profit: Tenax reported zero revenue, zero cost of revenue and zero gross profit in Q2 2026, consistent with the other recent quarterly income statements provided. The company has not yet demonstrated commercial operations.
  • Operating losses are widening: Q2 2026 operating expenses increased to $18.8 million from $11.8 million in Q2 2025 and $3.7 million in Q2 2024. The quarterly net loss reached $17.8 million, compared with $10.8 million and $3.6 million in those respective quarters.
  • Research and development spending is accelerating: Q2 2026 research and development expense was $12.9 million, more than double the $6.1 million reported in Q2 2025. Selling, general and administrative expense also rose to $5.9 million from $5.7 million in Q2 2025.
  • Heavy cash burn and dilution risk: Operating cash flow was negative $14.2 million in Q2 2026, following negative $9.3 million in Q1 2026 and negative $13.4 million in Q4 2025. Weighted average basic shares increased to 50.9 million in Q2 2026 from 39.6 million in Q2 2025 and 0.25 million in Q4 2023, highlighting substantial dilution from capital raising.

Overall, Tenax has materially improved its liquidity since 2024, but that improvement has been driven by equity and other financing rather than revenue growth. The latest statements show a company with significant cash and minimal reported debt, yet also escalating research costs, persistent losses and continued reliance on external capital. Investors should monitor cash burn, additional share issuance and progress toward revenue-generating operations.

11/17/26 08:41 PM ETAI Generated. May Contain Errors.

Tenax Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Tenax Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Tenax Therapeutics' net income appears to be on a downward trend, with a most recent value of -$52.60 million in 2025, falling from -$14.08 million in 2014. The previous period was -$17.60 million in 2024. See Tenax Therapeutics' forecast for analyst expectations on what's next for the company.

Tenax Therapeutics' total operating income in 2025 was -$56.39 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $56.39 million

Over the last 11 years, Tenax Therapeutics' total revenue changed from $49.29 thousand in 2014 to $0.00 in 2025, a change of -100.0%.

In the past 12 quarters, Tenax Therapeutics' cash and equivalents has ranged from $9.38 million in Q2 2024 to $118.76 million in Q1 2026, and is currently $113.73 million as of their latest financial filing in Q3 2026.

Tenax Therapeutics had total debt of $0.00 at the end of 2025, compared with none in 2024, and a 100.0% decrease since 2014.

Over the last 11 years, Tenax Therapeutics' book value per share changed from 2.50 in 2014 to 15.55 in 2025, a change of 520.7%.



Financial statements for NASDAQ:TENX last updated on 11/5/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners